03 Apr 2018

Decision in the case of Spencer Furman


The charge under Article 2.1 of the 2017 Tennis Anti-Doping Programme (the "Programme") against Spencer Furman has been dropped, following the grant of a Therapeutic Use Exemption (“TUE”).

Mr. Furman, a 21-year-old player from the USA, provided a urine sample on 9 September 2017 in association with his participation in the Qualifying Draw of the Atlantic Tire Championships, an ATP Challenger, held in Cary, NC, USA. That sample was found to contain D-amphetamine. D-amphetamine is a Non-Specified substance, which is prohibited under category S6(a) of the 2017 WADA Prohibited List (Stimulants), and therefore is also prohibited under the Programme.

On 3 November 2017, Mr. Furman was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample), and was Provisionally Suspended with effect from 13 November 2017.

Mr. Furman explained that he used an ADHD medication called Vyvanse that was prescribed to him by a doctor to help him concentrate while studying at university. This was accepted as the source of the D-amphetamine. On 27 February 2018, Mr. Furman applied for a retroactive TUE under Article 4.3(d) of the International Standard for TUEs (with supporting medical documentation). Article 4.3(d) provides that, where agreed by WADA and the Anti-Doping Organisation concerned, a retroactive TUE may granted on the grounds of fairness. WADA agreed that Mr. Furman should be granted a retroactive TUE.

As such, Mr. Furman is in possession of a valid TUE for the date on which he provided a positive sample. Accordingly, the charge against Mr. Furman has been dropped and the proceedings before the Independent Tribunal have been discontinued.